GENFIT Share Price Euronext Paris
Stocks
FR0004163111
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
Euronext Paris
|
||
| - EUR | - |
|
| 03/07 | Genfit soars on news of U.S. reimbursement for a product |  |
| 03/07 | Genfit's Liver Disease Blood Test Approved for US Medicare Reimbursement | MT |
| Market Cap | 69Cr 80Cr 65Cr 59Cr 110.83Cr 7.56TCr 111.13Cr 766.39Cr 297.39Cr 3.88TCr 300.82Cr 294.25Cr 13TCr | P/E 2026 * |
35.6x | P/E 2027 * | 91.5x |
|---|---|---|---|---|---|
| Enterprise Value | 64Cr 74Cr 60Cr 55Cr 102.61Cr 7TCr 102.89Cr 709.56Cr 275.34Cr 3.59TCr 278.51Cr 272.43Cr 12TCr | EV / Sales 2026 * |
6.37x | EV / Sales 2027 * | 5.02x |
| Free-Float |
86.89% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Prigent
CEO | Chief Executive Officer | 58 | 16/09/2019 |
Thomas Baetz
DFI | Director of Finance/CFO | 52 | 22/04/2021 |
Pejvack Motlagh
CTO | Chief Tech/Sci/R&D Officer | - | 27/11/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | 16/06/2017 | |
| Director/Board Member | 54 | 15/09/1999 | |
| Director/Board Member | 58 | 16/06/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.54% | -2.84% | -1.77% | +14.72% | 4.89TCr | |
| -0.40% | +1.03% | +418.57% | +523.39% | 4.5TCr | |
| -1.42% | +2.30% | +42.67% | +21.22% | 4.41TCr | |
| -1.22% | -2.31% | +4.82% | +74.90% | 4.07TCr | |
| +0.53% | -1.36% | +16.87% | +47.12% | 3.35TCr | |
| -0.21% | +9.14% | - | - | 1.78TCr | |
| -0.35% | -1.56% | +21.42% | +123.04% | 1.65TCr | |
| -1.01% | +0.50% | +13.91% | +31.45% | 1.47TCr | |
| -1.65% | -1.03% | +75.93% | +41.22% | 1.38TCr | |
| Average | -0.92% | +0.53% | +74.05% | +109.63% | 3.06TCr | |
| Weighted average by Cap. | -1.03% | +0.11% | +89.42% | +127.93% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 10Cr 12Cr 9.43Cr 8.61Cr 16Cr 1.1TCr 16Cr 111.4Cr 43Cr 564.06Cr 44Cr 43Cr 1.82TCr | 12Cr 14Cr 12Cr 11Cr 20Cr 1.36TCr 20Cr 137.91Cr 54Cr 698.32Cr 54Cr 53Cr 2.25TCr |
| Net income | 2.29Cr 2.66Cr 2.15Cr 1.97Cr 3.68Cr 251.02Cr 3.69Cr 25Cr 9.87Cr 128.79Cr 9.98Cr 9.77Cr 414.91Cr | 68L 79.02L 63.98L 58.44L 1.09Cr 75Cr 1.1Cr 7.56Cr 2.93Cr 38Cr 2.97Cr 2.9Cr 123.32Cr |
| Net Debt | -5.11Cr -5.94Cr -4.81Cr -4.39Cr -8.22Cr -560.87Cr -8.24Cr -57Cr -22Cr -287.76Cr -22Cr -22Cr -927.04Cr | -6.62Cr -7.69Cr -6.23Cr -5.69Cr -11Cr -726.06Cr -11Cr -74Cr -29Cr -372.52Cr -29Cr -28Cr -1.2TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
